5.16
-0.08(-1.53%)
Currency In USD
| Previous Close | 5.24 |
| Open | 5.27 |
| Day High | 5.31 |
| Day Low | 5.06 |
| 52-Week High | 7.37 |
| 52-Week Low | 2.41 |
| Volume | 1.16M |
| Average Volume | 1.04M |
| Market Cap | 402.01M |
| PE | -2.08 |
| EPS | -2.48 |
| Moving Average 50 Days | 5.21 |
| Moving Average 200 Days | 4.95 |
| Change | -0.08 |
If you invested $1000 in Solid Biosciences Inc. (SLDB) since IPO date, it would be worth $15.21 as of January 14, 2026 at a share price of $5.16. Whereas If you bought $1000 worth of Solid Biosciences Inc. (SLDB) shares 5 years ago, it would be worth $53.25 as of January 14, 2026 at a share price of $5.16.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101
GlobeNewswire Inc.
11 hours ago
- Duchenne: Dosed 33 participants in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of January 9, 2026; SGT-003 continues to be generally well tolerated using a steroid-only prophylactic immunomodulation regimen - - Duchenne: First participant enro
Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia
GlobeNewswire Inc.
Jan 12, 2026 9:15 PM GMT
- SGT-212 has received FDA Fast Track, Rare Pediatric Disease and Orphan Drug designations - - Dosing of the first participant in the Phase 1b FALCON trial has been completed, with initial data expected in H2 2026, subject to participant enrollment -
Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia
GlobeNewswire Inc.
Jan 12, 2026 1:05 PM GMT
Initial data from the Phase 1b FALCON trial expected in H2 2026, subject to participant enrollmentCHARLESTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company develo